—

MiniMed Group, Inc. Common Stock (MMED) — the peer cohort

As of 2026-10-15 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

MiniMed Group, Inc. Common Stock ranks 8 of 10 in its cohort on the Closelooknet composite (45/100) — the cohort is led by Halozyme Therapeutics Inc at 75/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
MMED MiniMed Group, Inc. Common Stock 45 71 21 26 — —
FPH.AU Fisher & Paykel Healthcare Corporation Ltd 61 86 70 26 ok 0.2%
ISRG Intuitive Surgical Inc 58 41 76 20 watch 30.4%
YPSN.SW Ypsomed Holding AG 56 75 62 28 info 9.5%
TECN.SW Tecan Group AG 49 96 27 52 ok 3.6%
EL.PA EssilorLuxottica S. A. 44 10 45 58 bear 53.2%
MDLN Medline Inc. Class A Common Stock 44 20 30 36 — —
HALO Halozyme Therapeutics Inc 75 98 94 47 ok 0.7%
DXCM DexCom Inc 66 87 80 34 watch 9.8%
ONC BeiGene, Ltd. 64 84 63 30 ok 2.9%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-10-15

Quick answers

Who are MiniMed Group, Inc. Common Stock's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Fisher & Paykel Healthcare Corporation Ltd (FPH.AU), Intuitive Surgical Inc (ISRG), Ypsomed Holding AG (YPSN.SW), Tecan Group AG (TECN.SW), EssilorLuxottica S. A. (EL.PA), Medline Inc. Class A Common Stock (MDLN), Halozyme Therapeutics Inc (HALO), DexCom Inc (DXCM) and others.

How does MMED score against its peers?

MiniMed Group, Inc. Common Stock's composite reads 45/100, ranking 8 of 10 in its cohort as of 2026-10-15; the cohort's highest composite is Halozyme Therapeutics Inc at 75/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Medical Instruments & Supplies. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.